The analysis of QOL in the patients of GERD with chronic liver disease after the treatment of PPI or H2-B

The analysis of QOL in the patients of GERD with chronic liver disease after the treatment of PPI or H2-B - The analysis of QOL in the patients of GERD with chronic liver disease after the treatment of PPI or H2-B

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002941

Enrollment

100

Registered

2009-12-25

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients of GERD with chronic liver disease

Interventions

sodium rabeprazole ranitidine hydrochloride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients evaluated by F-scale The patients evaluated by SF-8 The patients without gastric ulcer or duodenal ulcer The patients with chronic liver disease

Exclusion criteria

Exclusion criteria: The patients with allergy for sodium rabeprazole and ranitidine hydrochloride The patients with severe live failure The patients treated by Interferon or with malignant tumor

Design outcomes

Primary

Measure	Time frame
The symptons of upper gastrointestine evaluated by F-sacle	—

Secondary

Measure	Time frame
The symptons by SF-8 gastrointesitinal peptide	—

Countries

Japan

Contacts

Public ContactMAKOTO ARAI

CHiba University Hospital Gastroenterology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026